Stuart Poulton Biography and Net Worth

Chief Development Officer of Karyopharm Therapeutics

Stuart Poulton joined Karyopharm in February 2022 as Senior Vice President, Strategy and Portfolio Management and was promoted to Chief Development Officer in July 2022. Mr. Poulton is responsible for leading Karyopharm’s Product Strategy and Portfolio Management Team, Clinical Operations, Data Management, Medical Writing, and Quality.

Mr. Poulton has more than 25 years of experience in the global biotech and pharmaceutical space. He joined Karyopharm from AbbVie, where he served as the Vice President of Clinical Development Operations and previously as the Vice President for Portfolio Program Management. Mr. Poulton also spent more than a decade at Amgen, where he held leadership roles of increasing responsibility in global program and portfolio management. He started his career in clinical operations at Eli Lilly.

Mr. Poulton holds a Bachelor of Science in Pharmacology and Chemistry from the University of Sydney and a Master of Commerce in Marketing from the University of New South Wales.

What is Stuart Poulton's net worth?: The estimated net worth of Stuart Poulton is at least $264.08 thousand as of September 15th, 2025. Mr. Poulton owns 27,710 shares of Karyopharm Therapeutics stock worth more than $264,076 as of July 16th. This net worth estimate does not reflect any other assets that Mr. Poulton may own. Learn More about Stuart Poulton's net worth.
How do I contact Stuart Poulton?: The corporate mailing address for Mr. Poulton and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Stuart Poulton's contact information.
Has Stuart Poulton been buying or selling shares of Karyopharm Therapeutics?: Stuart Poulton has not been actively trading shares of Karyopharm Therapeutics in the last ninety days. Most recently, Stuart Poulton sold 401 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $6.43, for a transaction totalling $2,578.43. Following the completion of the sale, the executive vice president now directly owns 27,710 shares of the company's stock, valued at $178,175.30. Learn More on Stuart Poulton's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Sohanya Cheng (Chief Commercial Officer and Head of Business Development), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Richard Paulson (President and Chief Executive Officer), Stuart Poulton (Chief Development Officer), Reshma Rangwala (Chief Medical Officer & Head of Research), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,958 shares worth more than $19,037.72. The most recent insider tranaction occured on April, 21st when EVP Reshma Rangwala sold 449 shares worth more than $4,014.06. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/21/2026.

Stuart Poulton Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2025	Sell	401	$6.43	$2,578.43	27,710
7/29/2025	Sell	191	$4.37	$834.67	27,223
7/30/2024	Sell	192	$15.90	$3,052.80	21,775
2/15/2024	Sell	389	$19.95	$7,760.55	10,918
7/28/2023	Sell	189	$25.50	$4,819.50	10,419
2/15/2023	Sell	391	$47.85	$18,709.35	4,275

Stuart Poulton Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $9.53

$9.38

$9.86

50 Day Range

MA: $9.15

$7.14

$10.67

2 Week Range

Now: $9.53

$3.65

$10.99

Volume

315,583 shs

Average Volume

518,590 shs

Market Capitalization

$215.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8